Program
OM336
A development code.
Its studies are mostly in Anemia, Hemolytic, Autoimmune · Myositis, led by Lakefront Biotherapeutics NV.
Furthest: phase 1, since Jul 9, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lakefront Biotherapeutics NV | 22 open or running | phase 1since Jul 9, 2025 | Jul 9, 2025 | Dec 2026phase 1 · NCT07083960 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 9, 2025First study: phase 1 study in Anemia, Hemolytic, AutoimmuneFirst studyNCT07083960 · 32 planned · United States, Australia
- Nov 13, 2025Phase 1 study in MyositisNCT07229144 · 39 planned · New Zealand
Ahead
- Dec 2026Primary completion: phase 1 study in Anemia, Hemolytic, AutoimmuneNCT07083960
- Jun 2027Primary completion: phase 1 study in MyositisNCT07229144
TargetBeta
CD3E →read by rule
“OM336 is an engineered bispecific antibody directed against BCMA and CD3”study text, by rule · the study
Other programs on CD3E
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| etentamig | AbbVie | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| cevostamab | Hoffmann-La Roche | phase 3 | 8 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| pasritamig | Johnson & Johnson | phase 3 | 5 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| gocatamig | Merck | phase 3 | 4 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07229144Myositis · New Zealand | 1 | Recruiting | Jun 2027 | 39 |
| NCT07083960Anemia, Hemolytic, Autoimmune · United States, Australia | 1 | Recruiting | Dec 2026 | 32 |
How it is read
Names in the registry
- “OM336”, 2 entries
Codes read as this program: OM336.
Conditions, from the studies’ own filings
- Anemia, Hemolytic, Autoimmune, 1 study
- Myositis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.